Smoking Cessation Program in the Construction Sector

Summary

The main objective of this study is to identify the optimal adaptive smoking cessation program for the construction sector in terms of effectiveness, cost-effectiveness, and potential implementation.

Conditions

• Smoking Cessation
• Tobacco Use Cessation
• Tobacco Smoking

Interventions

DRUG

Nicorette

Participants will receive a 6-week supply of nicotine replacement treatment (NRT). Based on participants' self-report on the number of cigarettes smoked, these are the possible dosages of NRT gum (2 mg and 4 mg). Participants should not smoke and use the nicotine gum at the same time. Nicotine gum should only be used when cravings for cigarettes arise and should not be treated like regular chewing gum. It is not to be constantly chewed NRT will be distributed based on the treatment condition.

BEHAVIORAL

Tobacco Quit-line

The TQL is free, and the TQL counselor will provide three phone counseling sessions lasting approximately 15 minutes to devise a specific plan to quit smoking and arrange the delivery of 4 to 12 weeks of NRT based on need. Participants will be advised to request nicotine gums instead of patches to accommodate their job circumstances.

BEHAVIORAL

Brief Behavioral Counseling

The counseling session will discuss preparing to quit, coping with job-related stress, getting social support, the "5A's" for preventing relapse (Avoid, Alter, Alternatives, Anticipate, and Active), proper use of NRT, and last approximately 30 minutes.

BEHAVIORAL

Intensive Behavioral Counseling

Participants will receive four weekly counseling sessions which include information about how to quit, challenges, and short and long-term relapse prevention. Each session will last approximately 20 minutes.

Sponsors & Collaborators

• Florida Department of Health

  collaborator OTHER_GOV

• University of Miami

  lead OTHER

Principal Investigators

• Taghrid Asfar, MD · [email protected]

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-04-10

Primary Completion

2027-02-28

Completion

2027-02-28

FDA Drug

Yes

Countries

• United States

Study Locations